===
EQS-News: PharmaSGP Holding SE / Key word(s): Personnel
PharmaSGP Holding SE strengthens the Management Board to further accelerate growth
2024-06-21 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
PharmaSGP Holding SE strengthens the Management Board to further accelerate growth
. PharmaSGP expands the Management Board as of July 1, 2024 with Peter Gerckens as Chief Commercial Officer
(CCO), a newly created position
. Peter Gerckens will be responsible for international markets, sales and new businesses
Gräfelfing, June 21, 2024 - German OTC pharmaceutical company PharmaSGP Holding SE is expanding its existing management
team with Peter Gerckens as Chief Commercial Officer (CCO) as of July 1, 2024. With the newly created CCO position,
PharmaSGP is bringing additional management expertise into the company and thus further strengthens the foundation for
the continuation of the profitable growth course in the coming years.
Peter Gerckens (37) started his career in 2012 at Procter & Gamble in the marketing department and moved to McKinsey's
Munich office in 2013. There he advised clients on strategic and operational issues for over eight years, including in
the consumer goods industry. Before joining PharmaSGP, Mr. Gerckens was Managing Director of a market-leading,
medium-sized media company in Munich with more than 100 employees. His responsibilities there included finance,
marketing and several business units. In his role as CCO at PharmaSGP, Mr. Gerckens will be responsible for the
expansion of international markets, sales and new businesses.
Peter Gerckens is a business economist and holds a Bachelor's degree (B.A.) from the University of St. Gallen, a
Master's degree (M.Sc.) from the London School of Economics and an MBA from Harvard Business School.
Natalie Weigand, CEO of PharmaSGP: "PharmaSGP has been pursuing a successful growth strategy for years and was able to
generate revenues of more than EUR100 million for the first time in 2023 with a continued attractive adjusted EBITDA
margin of over 30%. In order to further increase our market share in the dynamically growing healthcare and
pharmaceutical market, we are now strengthening our management team with a Chief Commercial Officer. In Peter Gerckens,
we have gained an experienced manager with strong implementation skills for this position and we are convinced that he
will make a decisive contribution to achieving our ambitious growth targets."

Peter Gerckens


CONTACT
cometis AG
Claudius Krause
Phone: +49-611-20585528
Email: ir@pharmasgp.com

ABOUT PHARMASGP HOLDING SE
PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals
and other healthcare products that are marketed with a focus on the pharmacy distribution channel. These products are
mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.
The Company's core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related
ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families
RubaXX^® for rheumatic pain and Restaxil^® for neuralgic pain. Furthermore, PharmaSGP also offers leading products
against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in
2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy,
Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan^®, Formigran
^®, Spalt^® and Kamol^®, thus also strengthening or developing the indications pain and sleep disorder. The sales
territory was expanded to include Switzerland and Eastern Europe. In 2023, PharmaSGP generated revenues of EUR101.1
million at an adjusted EBITDA margin of 33.7%.
In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by
PharmaSGP's product offering, increase PharmaSGP's European footprint, and accelerate its growth strategy especially by
capitalizing on selected M&A opportunities.
2024-06-21 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      PharmaSGP Holding SE 

Lochhamer Schlag 1
82166 Gräfelfing
Germany

E-mail:       ir@pharmasgp.com 
Internet:     https://pharmasgp.com 
ISIN:         DE000A2P4LJ5 
WKN:          A2P4LJ 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 

Munich, Tradegate Exchange
EQS News ID: 1930049

End of News EQS News Service
===
1930049 2024-06-21 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=96bc5ee46df4620f856776eea1f0b8b9

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1930049&application_name=news

END) Dow Jones Newswires

June 21, 2024 01:30 ET (05:30 GMT)